Loading
Latest filing published 17 Jun 2022 for CASI Pharmaceuticals, Inc., €103k. Read the official filing
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Wei-Wu He, listed as chief executive, appears in our data through filings on CASI Pharmaceuticals, Inc. shares, published by SEC (Form 4). In total, 3 filings cover trades dated from 18 August 2021 to 13 June 2022.
No open-market sale appears; the market trades are 3 purchases worth €608k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. So far in 2022, the count stands at 1 purchase and no sales.
A typical purchase (the median) is worth €175k. None of the 3 purchases we analysed coincided with buying by another insider of the same company within 30 days.
The record was last updated on 17 June 2022 with an open-market purchase (€103k) in CASI Pharmaceuticals, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations